Transcription

1 Certain technical and administrative guidelines with regard to the public-to-private and financing transaction between Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation ISIN Code NL and -. I U*'*- ' M K ft?*'i" uniqure B.V. ISIN Code NL Technical Information Memorandum to Admitted Institutions of NYSE Euronext Amsterdam N.V. and Eurociear Netherlands IMPORTANT INFORMATION - READ CAREFULLY This Technical Information Memorandum (the "TIM") is intended only to inform the members of NYSE Euronext Amsterdam and the admitted institutions of Eurociear Netherlands (the "Admitted Institutions") about certain administrative and technical guidelines in relation to the public-to-private and financing transaction (the "Transaction") between Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) ("AMT") and uniqure B.V. ("uniqure"), as further set out in a shareholder circular dated 17 February 2012 (the "Shareholder Circular") addressed to all AMT shareholders. As indicated and detailed in the Shareholders Circular, the Transaction inter alia encompasses the dissolution and liquidation of AMT, which shall result in the distribution of depositary receipts (certificaten van aandelen) for (class B) ordinary shares in uniqure ("uniqure DRs") plus any additional liquidation surplus (the "Distribution") to holders of shares in AMT with certain eligible AMT shareholders being entitled to exchange their uniqure DRs for an equal number of (class A) ordinary shares in uniqure (the "Exchange Offer"), and ultimately AMT delisting from NYSE Euronext in Amsterdam and ceasing to exist. This TIM is not intended to serve as a substitution for the Shareholder Circular, which should be read in their entirety for information on the Transaction. This TIM may only be disclosed or distributed to Admitted Institutions and only in accordance with the restrictions in the Shareholder Circular and as described herein. Any other persons (including holders of AMT shares) should always be referred to and take notice of the Shareholder Circular for information on the Transaction. The definitions used in this TIM are set out in the Shareholder Circular. For further detailed information reference is made to the Shareholder Circular and the press releases dated 17 February, 30 March and 6 April Copies of the Shareholder Circular can be obtained in electronic form from AMT's website (www. or can be obtained in hard copy free of charge through Kempen & Co N.V., (telefax number: +31 (0) or address: or from AMT (telephone number: +31 (0) ; telefax number: +31 (0) ). The Shareholder Circular shall prevail in case of inconsistency with this TIM. By distributing this TIM, Kempen & Co N.V. does not accept any responsibility or liability for (and no representation, warranty or assurance of any kind, express or implied, is or will be made as to or in relation to) the accuracy or completeness of this TIM or the Shareholder Circular. This TIM does not constitute an offer or invitation for the sale, purchase, exchange or transfer of any securities or any recommendation in relation to Transaction, and is not intended to form the basis of any investment decision regarding AMT and/or uniqure.

2 Restrictions The Transaction has been entered into and shall be implemented with due observance of such statements, conditions and restrictions as are included in the Shareholders Circular. This TIM nor the Shareholders Circular does contain, constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase any securities and neither this TIM nor the Shareholder Circular or anything contained herein or therein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever. It is specifically noted that the Distribution of the uniqure DRs to the AMT shareholders shall be an allocation of such securities where there is no element of choice on the part of the recipient, including no right to repudiate the allocation. Consequently, the Distribution of the uniqure DRs is no "offer of securities to the public" in the meaning of Chapter 5.1 of the Financial Supervision Act (Wet op het financieel toezicht) and article 2.1 (d) of the Prospectus Directive (2003/71 /EC /73/EU). The Distribution does therefore not require the publication of a prospectus, nor does any other element of the Transaction require such a publication of a prospectus. Neither the uniqure DRs nor the shares in uniqure or AMT have been (nor will be) registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold or allotted except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. There will be no public offer of uniqure DRs, shares in uniqure or AMT in the United States or elsewhere No uniqure DRs or shares in uniqure or AMT will be offered or allotted directly or indirectly into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States, unless an exemption from registration under the US Securities Act, is available. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. Accordingly, copies of this TIM and/or the Shareholders Circular and any related offering documents will not and must not be mailed or otherwise transmitted, distributed or forwarded in or into the United States. Neither this TIM nor the Shareholders Circular has been submitted to or reviewed by the US Securities and Exchange Commission (the "SEC") or any state securities commission of any other jurisdiction, and neither the SEC nor any such state securities commission of any other jurisdiction has (a) approved or disapproved the allotment of the uniqure DRs or their exchange in shares in uniqure pursuant to the Exchange Offer, (b) passed upon the merits or fairness of the allotment, or (c) passed upon the adequacy or accuracy of the disclosure in this TIM or the Shareholders Circular. Any representation to the contrary is a criminal offence in the United States.

3 Technical information regarding the Transaction On 16 February 2012, Forbion Co-Investment II Coöperatief U.A., Coöperatieve AAC LS U.A. and Forbion Co-Investment Coöperatief U.A. (collectively "Forbion"), uniqure, a newly incorporated and privately held entity controlled by Forbion, and AMT 1 entered into an agreement. As further set out in the Shareholder Circular, the transaction that Forbion, uniqure and AMT agreed (the "Transaction") effectively regards a public-to-private transaction combined with AMT's gene therapy business being provided with additional funding. It consists of five main elements: 1. the disposal by AMT of its entire business and all its historic, actual and future assets and liabilities (collectively herein also referred to as the "Business") to uniqure by way of a contribution in kind (inbreng in natura) on depositary receipts (certificaten van aandelen) for (class B) ordinary shares in uniqure ("uniqure DRs") which are issued to AMT as consideration for the Business, which disposal (the "Disposal") effectively transforms AMT in a listed shell company and with the uniqure DRs issued to it as its single asset and without any known financial liabilities, in combination with; 2. a commitment by Forbion managed funds to provide equity funding of 6.0 million to uniqure, as acquirer of the Business 2 ; 3. the dissolution and liquidation of AMT (the "Dissolution"), which shall result in; 4. the distribution to the AMT shareholders of one uniqure DR for each AMT share held on the Distribution Record Date (as defined herein) plus any additional liquidation surplus (the "Distribution"), with each AMT shareholder that on the Distribution Record Date holds at least 5% of the shares in AMT being entitled to exchange its uniqure DRs for an equal number of (class A) ordinary shares in uniqure (the "Exchange Offer"), and ultimately, 5. AMT delisting from NYSE Euronext in Amsterdam and ceasing to exist (the "Delisting"). The overall result of the Transaction will be that if a person holds shares in AMT on the Distribution Record Date, such person's investment in the Business will effectively be transformed from a shareholding in the listed company AMT, to a holding of depositary receipts for (class B) ordinary shares in the unlisted, private company uniqure (or potentially a holding of (class A) ordinary shares in uniqure if the person in question is entitled to exchange his or her uniqure DRs in such shares pursuant to the Exchange Offer). On Friday 30 March 2012, an extraordinary general meeting of shareholders of AMT (the "Extraordinary General Meeting") approved the Transaction. On Thursday 5 April 2012 (the "Completion Date"), the Disposal was completed. As consideration for its disposed Business, AMT received 31,101,065 uniqure DRs. Immediately following the completion of the Disposal and consequently as per 5 April 2012, the Dissolution of AMT as resolved by the Extraordinary General Meeting has become 1 At the time it entered into the agreement, AMT was not yet dissolved. The company is dissolved and in liquidation as per 5 April As AMT announced on 30 March 2012, the condition precedent pursuant whereto Forbion's financing commitment and its obligation to complete the Transaction was conditional on AMT being able to obtain irrevocable commitments from one or more additional investors to provide at least 1.0 million in equity funding to uniqure has been waived by Forbion.

4 effective, with the company's former management board members being the liquidators that shall liquidate AMT's dissolved property. uniqure DRs The uniqure DRs are depositary receipts (certificaten van aandelen) for class B ordinary shares. The uniqure DRs are issued (without uniqure's co-operation) by Stichting Administratiekantoor uniqure B.V., a trust foundation (stichting administratiekantoor) that holds the underlying class B ordinary shares on trust for the holders of the uniqure DRs. The uniqure DRs will not be admitted to trading on a regulated market or on a multilateral trading facility. Consequently there will effectively be no market for uniqure DR holders to sell their uniqure DRs. uniqure DRs will be freely transferable, however, and transfers of uniqure DRs may be settled through the book entry system operated by Euroclear Netherlands. uniqure is currently looking into the possibilities of facilitating the trade of uniqure DRs between holders thereof, in particular via the NPEX platform. Further information on the Distribution, the Exchange Offer and the Delisting Distribution Because AMT's dissolved property consists of the uniqure DRs issued to AMT in the context of the Disposal without it having any known financial liabilities, and the financial condition is expected to justify the same, it is intended that AMT's liquidators make an advance liquidation distribution to the AMT shareholders by distributing and allocating to each such shareholder one uniqure DR for each AMT share held on the Distribution Record Date (the "Advance Distribution"). The Distribution Record Date shall to be 23 April 2012 and the date on which the Advance Distribution of the uniqure DRs shall take place is 26 April 2012 (in each case subject to extension of the timetable for the Transaction). In the unlikely event that any liquidation surplus would remain after the Advance Distribution, the liquidators will make a final liquidation distribution to the AMT shareholders of such remaining liquidation surplus as soon as reasonably possible after the liquidation accounts and plan of distribution have become final (such final distribution, if any, the "Final Distribution", the Advance Distribution and the Final Distribution (if any) also, the "Distribution"). The Distribution of the uniqure DRs to the AMT shareholders will be settled through the book entry system operated by Euroclear Netherlands, and will result in one uniqure DR being credited in the securities account of each AMT shareholder for each AMT share held on the Distribution Record Date. Consequently, to receive uniqure DRs, a person must hold AMT shares on the Distribution Record Date. To hold AMT shares on the Distribution Record Date, a shareholder must have bought such shares before the Ex Date, which is 19 April 2012 (i.e. the second business day prior to the Distribution Record Date) (subject to extension of the timetable for the Transaction). Conversely, shareholders that do not want to receive uniqure DRs, must sell their AMT shares before the Ex Date. For completeness sake it is noted that the AMT shares will not be cancelled or otherwise cease to exist upon the Distribution of the uniqure DRs. The AMT shares will continue to exist until the Dissolution is finalised and AMT ceases to exist, which is expected to occur in the summer of 2012.

5 Exchange Offer Each AMT shareholder holding at least 5% of the shares in the capital of AMT on the Distribution Record Date shall be entitled to exchange its uniqure DRs for an equal number of ordinary shares (class A) in uniqure, subject to such shareholder becoming party to the uniqure Shareholder Agreement. An AMT shareholder that wishes to exchange its uniqure DRs for ordinary shares (class A) in uniqure pursuant to the Exchange Offer must give written notice thereof to AMT within ten business days after the Distribution Record Date, i.e. ultimately on 9 May 2012 (subject to extension of the timetable for the Transaction). The written notice should be accompanied with evidence of their AMT shareholding. More information on the Exchange Offer can also be found in the trust conditions (administratievoorwaarden) of Stichting Administratiekantoor uniqure B.V. Delisting When the liquidation ends, AMT and its shares shall cease to exist. This shall effectively also result in AMT's delisting, to the extent the delisting cannot be achieved at an earlier date in consultation with Euronext Amsterdam and subject to such conditions as Euronext Amsterdam may propose. Timetable of principle events Extraordinary General Meeting Completion Date Dissolution coming into effect Ex Date Distribution Record Date (after close of trading on NYSE Euronext in Amsterdam) Advance Distribution Final date Exchange Offer End of liquidation and Final Distribution (if any) Delisting 30 March April April April 2012 (i.e. two business days prior to the Distribution Record Date) 23 April 2012 (i.e. the tenth business day after the Dissolution coming into effect) 26 April 2012 (i.e. three business days after the Distribution Record Date) 9 May 2012 expected summer 2012 expected summer 2012 Each of the above dates is subject to extension of the timetable for the Transaction. Any extension of the timetable for the Transaction shall be announced in a press

6 release at least one business day before the originally set date of the event that is to be extended and reset at a later date. Security codes AMT shares ISIN Code: NL Common Code: Symbol: "AMT" uniquredrs ISIN Code: NL Common Code: Commission to Admitted Institutions Admitted Institutions shall receive from Kempen & Co N.V. on behalf of AMT a commission of 1.00 (one euro) per AMT custody client. The commission must be claimed from AMT through Kempen & Co N.V. within ten (10) calendar days of the date on which the Advance Distribution is made. Non-US Beneficial Ownership Statement Reference is made to the "Restrictions" paragraph above, and specifically to the restrictions regarding the offering, distribution and allocation of uniqure DRs into the United States. To ensure compliance with these restrictions, uniqure has been marked as a Non-US Beneficial Ownership fund and each Admitted Institution shall be requested to certify by means of a Certificate of Non-US Beneficial Ownership (to be provided separately by Euroclear Netherlands) that it shall not distribute or allocate uniqure DRs to US persons. Further information and announcements For further information on the Transaction, reference should be made to the Shareholder Circular and to AMT's press releases of 17 February, 30 March and 6 April The Shareholder Circular shall prevail in case of inconsistency with this TIM. Copies of the Shareholder Circular can be obtained in electronic form from AMT's website (www. or can be obtained in hard copy free of charge through Kempen & Co N.V., (telefax number: +31 (0) or address: or from AMT (telephone number: +31 (0) ; telefax number: +31 (0) ). Any further announcements of AMT concerning the Transaction will be issued by press release and on the AMT website ( Contact details Kempen & Co N.V. Giuseppe Montalbano Dick Siemensma Telephone: +31 (0) , Telephone: +31 (0) ,

20 December 2012 FIFTH SUPPLEMENT TO THE BASE PROSPECTUS IN RESPECT OF THE EURO 5,000,000,000 DEBT ISSUANCE PROGRAMME F. van Lanschot Bankiers N.V. (incorporated in the Netherlands with its statutory seat

RoodMicrotec N.V. (the Company) Warrant plan relating to the granting of warrants (the Plan) certified by. 1. Introduction On 25 September 2013, the management board of the Company (the Management Board)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext

LETTER OF TRANSMITTAL This letter of transmittal (this Letter of Transmittal ), together with the exchange forms attached hereto (each, an Exchange Form, ), relate to the offer to deliver (the U.S. Exchange

FOR IMMEDIATE RELEASE 10 July 2006 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO CANADA RECOMMENDED FINAL OFFERS * by AIRPORT DEVELOPMENT AND INVESTMENTLIMITED a company

To: Bucharest Stock Exchange Financial Supervisory Authority Current report according to Article 99 of the Code of the Bucharest Stock Exchange, Title II, Issuers and Financial Instruments. Events to be

Press release Date 18 February 2015 This is a press release by SHV Investments Ltd. pursuant to the provisions of Section 15 paragraph 2 of the Decree on Public Takeover Bids (Besluit openbare biedingen

This press release and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America

CONTRIBUTION AGREEMENT of INCROWD ALABAMA FUND I, LLC INSTRUCTIONS TO INVESTORS EACH PROSPECTIVE INVESTOR IN INCROWD ALABAMA FUND I, LLC (THE COMPANY ) SHOULD EXAMINE THE SUITABILITY OF THIS TYPE OF INVESTMENT

Joint Press Release This is a joint press release by Corio and Klépierre S.A. pursuant to the provisions of Section 10 Paragraph 3 and Section 18 Paragraph 3 of the Netherlands Decree on Public Takeover

N.V. Nederlandse Gasunie announces Tender Offer in respect of its 1,400,000,000 6.00 per cent. Fixed Rate Notes due 30 October 2013 (ISIN: XS0396192535) NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON

This is a press release by Klépierre S.A. and Corio N.V. pursuant to the provision of Section 4 Paragraph 3 of the Netherlands Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) in connection

DESCRIPTION OF THE PLAN PURPOSE 1. What is the purpose of the Plan? The purpose of the Plan is to provide eligible record owners of common stock of the Company with a simple and convenient means of investing

Transfers of securities to RBS plc pursuant to Part VII of the UK Financial Services and Markets Act 2000 On 6 February 2010 ABN AMRO Bank N.V. (registered with the Dutch Chamber of Commerce under number

This document is important and requires your immediate attention. If you are in doubt as to how to deal with it, you should consult your investment dealer, stockbroker, bank manager, lawyer or other professional

IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the attached Consent Solicitation Memorandum whether received by email or as a result of electronic

DISPLAY VERSION ST IVES PLC ST IVES LONG TERM INCENTIVE PLAN 2010 Approved by shareholders of the Company on Adopted by the board of the Company on The Plan is a discretionary benefit offered by St Ives

STICHTING HOLLAND HOMES ORANJE II with its corporate seat in Amsterdam, the Netherlands (the "Issuer") This report ("Report") is made available by Stichting Security Trustee Holland Homes Oranje II (the

SUCCESS OF THE OFFER TO CREATE THE LEADING PAN-EUROPEAN COMMERCIAL PROPERTY COMPANY: 80% of Rodamco Shares tendered to the offer of Unibail UNIBAIL DECLARES THE EXCHANGE OFFER FOR ALL OUTSTANDING SHARES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this application form and

5 October 2011 The Royal Bank of Scotland plc (Incorporated in Scotland with limited liability under the Companies Acts 1948 to 1980, registered number SCO90312) 200 Put Warrants linked to the performance

THIS INDICATIVE TERM SHEET COMPRISES ONLY A SUMMARY OF THE TERMS OF THE PROPOSED CONVERTIBLE BONDS (THE BONDS ). THE INFORMATION HEREIN IS INDICATIVE ONLY. ALTHOUGH THE INDICATIVE INFORMATION HEREIN IS

1 November 2013 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Lekoil Limited ("Lekoil" or the "Company") Completed placing of new

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever

The Offer will expire on 16 February 2011 at 17:45 hours Dutch time (11:45 a.m. New York time), unless extended Offer Document Dated 8 December 2010 regarding the recommended cash offer for (i) all issued

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever

Standard Conditions for Grants Made by the World Bank Out of Various Funds Dated February 15, 2012 ARTICLE I Introductory Provisions Section 1.01. Application of Standard Conditions. These Standard Conditions

MEGA BRANDS INC. Offer of a cashless exercise right to the holders of the Warrants referred to below (CUSIP 58515N113) MEGA Brands Inc. (the Corporation ) hereby offers to the Holders (as defined below)

THIS PROSPECTUS AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to consult immediately,

DECISION NO (94/R) OF 2005 CONCERNING THE LISTING OF DEBT SECURITIES The Chairman of the Board of Directors of the Stocks and Commodities Authority has, After pursuing the provisions of Federal Law No.

The distribution of this press release, directly or indirectly, in or into the United States, Canada, Australia or Japan is prohibited. This press release (and the information contained herein) does not

Description of the Voting Process for Creditors and Shareholders November 2012 Disclaimer WHILE JSC BTA BANK (THE "BANK or BTA ) HAS USED ALL REASONABLE EFFORTS TO ENSURE THAT THE INFORMATION CONTAINED

1 NATIONAL CONTRACTORS INSURANCE COMPANY, INC., A RISK RETENTION GROUP NOTICE SUBSCRIPTION AND SHAREHOLDERS AGREEMENT This policy is issued by your risk retention group. Your risk retention group may not

IMPORTANT NOTICE IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the Base Prospectus (the Base Prospectus ) attached to this electronic transmission

18 NCAC 06A.1706 RECORD-KEEPING REQUIREMENTS FOR INVESTMENT ADVISERS (a) Except as otherwise provided in Paragraph (j) of this Rule, every investment adviser registered or required to be registered under

U.S. AND GLOBAL EMPLOYEE STOCK PURCHASE PLANS SUMMARY OF KEY TERMS January 1, 2009 EXECUTIVE SUMMARY This summary highlights some features of the Thomson Reuters U.S. Employee Stock Purchase Plan and the

UNOFFICIAL TRANSLATION Explanatory Memorandum Article 1, paragraphs 491 to 500, of Law No 228 of 24 December 2012, hereinafter referred to the Law, has introduced a tax on financial transactions applying

Retail Shareholder Q&A This Q&A contains information derived from, but does not summarise, the announcement of the Offer by Royal Dutch Shell to acquire BG Group dated 8 April 2015 (the Announcement ).

(text consolidated at 20 June 2012)* * 1) The Rules adopted by the Supervisory Board by Resolution No. 1/1110/2006 dated 4 January 2006, as amended by the Exchange Supervisory Board: - by Resolution No.

General Investment Conditions This is a translation of the original Dutch text. This translation is furnished for the customer s convenience only. The original Dutch text will be binding and shall prevail

Macquarie Group Limited (ASX: MQG) MARCH 2015 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES MACQUARIE GROUP LIMITED ACN122169 279 This is an important document offering eligible shareholders the

SHARE PURCHASE PLAN 14 November 2014 You should read this document in full. This booklet contains important information. You should read this document in full and seek advice from your financial, taxation

The information in this Red Herring Prospectus is not complete and may be changed. The Issue is meant only for Qualified Institutional Buyers and is not an offer to any other person or class of investors

TERMS AND CONDITIONS OF THE RIGHTS ISSUE Background Citycon Oyj (the "Company") has on 25 May 2015 signed an agreement to acquire all the shares in Sektor Gruppen AS, Norway s second largest shopping centre

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR AUSTRALIA 3I INFRASTRUCTURE LIMITED

This document contains selected sections of the South African Companies Act and the Delaware General Corporation Law applicable to mergers and acquisitions. It is intended to be used in connection with

REPUBLIC OF CYPRUS INTERNATIONAL COLLECTIVE INVESTMENT SCHEMES LAW (No 47(I) of 1999) English translation prepared by The Central Bank of Cyprus ARRANGEMENT OF SECTIONS PART I PRELIMINARY AND GENERAL Section

KANSAS CITY LIFE INSURANCE COMPANY NOTICE OF SPECIAL MEETING OF SHAREHOLDERS To Be Held December 15, 2015 Notice is hereby given that a Special Meeting of Shareholders of Kansas City Life Insurance Company,

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever

PROSPECTUS August 15, 2011 INTRICON CORPORATION Summary of the 2007 Employee Stock Purchase Plan This document constitutes part of a prospectus covering securities that have been registered under the Securities

FOURTH SUPPLEMENT TO THE BASE PROSPECTUS DATED 11 JULY 2011 RELATING TO THE DEBT ISSUANCE PROGRAMME OF SNS BANK N.V. AND SNS REAAL N.V. DATED 25 May 2012 SNS BANK N.V. (incorporated under the laws of The

Level: 5 From: 5 Wednesday, June 13, 2007 5:19 pm mac5 3685 Important Notice : 3685 Important Notice IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. IMPORTANT: